JP2014512333A - 脂質低下抗糖尿病薬 - Google Patents
脂質低下抗糖尿病薬 Download PDFInfo
- Publication number
- JP2014512333A JP2014512333A JP2013549539A JP2013549539A JP2014512333A JP 2014512333 A JP2014512333 A JP 2014512333A JP 2013549539 A JP2013549539 A JP 2013549539A JP 2013549539 A JP2013549539 A JP 2013549539A JP 2014512333 A JP2014512333 A JP 2014512333A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- diabetes
- composition
- metformin
- fatty acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/52—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing groups, e.g. carboxylic acid amidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
- C07C251/04—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C251/06—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
- C07C251/08—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton being acyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Plant Pathology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Vascular Medicine (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
本出願は、その内容を参照により本明細書に組み込む、2011年1月12日出願の米国仮特許出願第61/461,113号および2012年1月11日出願の米国特許出願第13/348,265号の優先権を主張する。
エイコサペンタエン酸:
この実施例は、本発明の開発に使用した単離したラットの灌流心臓モデルについて記述する。検査は、一定容積の単離したラットの心臓標本を用いて行う。急性的に糖尿病になったオスのBB/Wラットと非糖尿病の年齢をマッチさせた(3〜4ヶ月)コントロールとをヘパリン(1000u;腹腔内)により事前に処置し、続いてペントバルビタールナトリウム(65mg/kg;腹腔内)により処置する。足の反射のないことにより判定される深い麻酔が達成された後、その心臓を速やかに摘出し、氷で冷やした生理食塩水中に入れる。その静止した心臓を、それらの摘出後2分以内に大動脈中の非再循環モデルで逆行灌流させる。最大左心室圧(LVDP)を圧力トランスジューサーに接続されている高圧管を有する左心室内のラテックス製の風船を用いて測定する。灌流圧を灌流ラインから離れた高圧管を用いて監視する。血行動態計測を4チャンネルのGouldレコーダーに記録する。そのシステムは、灌流媒体を急速に変化させることを可能にする共通の温度制御以外は別々の人工肺、ポンプおよび気泡トラップを備えた2つの平行する灌流ラインを有する。その心臓は、正確なローラーポンプを用いて灌流する。その灌流液は、118mMのNaCl、0.47mMのKCl、12mMのCaCl2、12mMのMgCl2、25mMのNaHCO3および基質のグルコース11mMからなる。その灌流装置は、全状況下で心臓温度を37±0.5℃に維持するために灌流液および灌流管の周りの水ジャケットのために加熱バスを使用して温度を厳重に制御する。室温の容器中の酸素を送り込んだ灌流液を、37℃の蒸留水で取り巻かれている25フィートの薄肉のシリコーンチューブを通過させ、95%酸素を飽和させる。その灌流液は、次に水ジャケットした(37℃)管に入り、水ジャケットした気泡トラップを通って心臓に至る。この調整は、規定どおり3〜4時間にわたって安定している優れた酸素化を提供する。
この実施例は、糖尿病コントロール心臓、処置した糖尿病の心臓、処置した非糖尿病心臓、およびコントロールの単離した心臓におけるゼロフロー虚血の検査に使用した手順を記述する。糖尿病コントロール(DC)、処置した糖尿病(DZ)、正常(C)のコントロールおよび処置した正常(CZ)の心臓を、20分間の正常酸素圧の灌流、続いての20分間の灌流液の流れが完全に止められるゼロフローの虚血、続いての60分間の再灌流にかける。心臓は、10μMのメトホルミンエイコサペンタエン酸により処置する。メトホルミンエイコサペンタエンで処置した糖尿病群(DZ)においては、心臓を正常のKrebs−Henseleit緩衝液 による10分間の正常酸素圧の灌流および10μMのメトホルミンエイコサペンタエン酸を含有するKrebs−Henseleit緩衝液による10 分間の正常酸素圧の灌流にかける。それらの心臓を、次に、20分間のゼロフローの虚血に、続いて60分間の再灌流にかける。再灌流条件のばらつきを避けるために、DCおよびDZ心臓は両方とも正常のKrebs−Henseleit緩衝液により再灌流する
この実施例は、糖尿病コントロール心臓、処置した糖尿病の心臓、処置した非糖尿病心臓、および非糖尿病のコントロールの単離した心臓における低流動性虚血の検査のために使用する手順を記述する。糖尿病コントロール心臓(DC)を、20分間の流速12.5mL/分の正常酸素圧の灌流に、続いて灌流の流れを正常な灌流の約10%である1.25mL/分に減速した30分間の低流動性虚血に、続いて正常な流速(12.5mL/分)における30分間の再灌流にかける。メトホルミンエイコサペンタエン酸で処置された糖尿病群または非糖尿病群(DZまたはCZ)において、心臓を、正常のKrebs−Henseleit緩衝液による10分間の正常酸素圧の灌流(流速12.5mL/分) および10μMの メトホルミンエイコサペンタエン酸を含有するKrebs−Henseleit緩衝液による10分間の正常酸素圧の灌流にかける。 それらの心臓を、30分間の低フローの虚血(流速12.5mL/分)および正常な流速(12.5mL/分)における30分間の再灌流にかける。
{[アミノ(イミノ)メチル]アミノ}(ジメチルアミノ)メタニミニウム(5Z,8Z,11Z,14Z,17Z)−エイコサ−5,8,11,14,17−ペンタエノアート)の調製
{[アミノ(イミノ)メチル]アミノ}(ジメチルアミノ)メタニミニウム (4Z,7Z,10Z,13Z,16Z,19Z)−ドコサ−4,7,10,13,16,19−ヘキサン酸の調製
{[アミノ(イミノ)メチル]アミノ}(ジメチルアミノ)メタニミニウム (5Z,8Z,11Z,14Z,17Z)−ドコサ−5,8,11,14,17−ペンタ塩酸の調製
実施例1の化合物の水溶性を、エイコサペンタエン酸(EPA)の水溶性と比較した。
Claims (15)
- RHによって表される、少なくとも1つの多価不飽和脂肪酸との、メトホルミンの塩である、式Iの構造を有する組成物、
- 前記多価不飽和脂肪酸RHがオメガ3脂肪酸である、請求項1に記載の組成物。
- RHが1〜3のヒドロキシ基で任意で置換されるオメガ3多価不飽和C16〜24脂肪酸であることを特徴とする、請求項1に記載の組成物。
- RHが、オメガ3の不飽和結合に加えて、脂肪酸鎖に合計4または5の不飽和結合を有する、20または22の炭素原子の脂肪酸であることを特徴とする、請求項2または3に記載の組成物。
- RHがレゾルビンD1、D2、D3、D4、E1、およびE2から成る群から選択されることを特徴とする、請求項1に記載の組成物。
- 前記多価不飽和脂肪酸RHがエイコサペンタエン酸である、請求項1に記載の組成物。
- 前記多価不飽和脂肪酸がドコサヘキサエン酸である、請求項1に記載の組成物。
- Rが多価不飽和脂肪酸の混合物であることを特徴とする、請求項1に記載の組成物。
- 前記多価不飽和脂肪酸がエイコサペンタエン酸とドコサヘキサエン酸との混合物を含む、請求項8に記載の混合物。
- 請求項1〜9のいずれか一項に記載の医薬組成物、および薬学的に許容可能な担体、ビヒクルまたは希釈剤。
- a)請求項1〜10のいずれか一項に記載の化合物を含む単位剤形;b)キットの使用方法に関する指示;およびc)前記単位剤形を収容するための少なくとも1つの容器を含むキット。
- 糖尿病、トリグリセリドの上昇、前糖尿病、肥満、心不整脈、心筋症または心筋梗塞から選択される哺乳類の症状の治療のための方法であって、請求項1〜10のいずれかに従う化合物を治療に有効量投与することを含む方法。
- 糖尿病、トリグリセリドの上昇、前糖尿病、肥満、心不整脈、心筋症または心筋梗塞から選択される哺乳類の症状を治療するための、請求項1に記載の組成物。
- 糖尿病、トリグリセリドの上昇、前糖尿病、肥満、心不整脈、心筋症または心筋梗塞から選択される哺乳類の症状を治療するための薬剤の調製のための、請求項1に記載の組成物の使用。
- a)好適なメトホルミン塩からメトホルミンの遊離塩基を新しく調製すること;およびb)新しく調製したメトホルミンの遊離塩基を、エイコサペンタエン酸、ドコサヘキサエン酸、またはそれらの混合物と、約1℃から約60℃の間の温度で反応させることを含む、請求項1に記載の組成物を製造するための方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161461113P | 2011-01-12 | 2011-01-12 | |
US61/461,113 | 2011-01-12 | ||
US13/348,265 | 2012-01-11 | ||
US13/348,265 US20120178813A1 (en) | 2011-01-12 | 2012-01-11 | Lipid-lowering antidiabetic agent |
PCT/US2012/021070 WO2012097144A1 (en) | 2011-01-12 | 2012-01-12 | Lipid-lowering antidiabetic agent |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014512333A true JP2014512333A (ja) | 2014-05-22 |
JP2014512333A5 JP2014512333A5 (ja) | 2015-03-12 |
JP5911514B2 JP5911514B2 (ja) | 2016-04-27 |
Family
ID=46455756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013549539A Expired - Fee Related JP5911514B2 (ja) | 2011-01-12 | 2012-01-12 | 脂質低下抗糖尿病薬 |
Country Status (12)
Country | Link |
---|---|
US (4) | US20120178813A1 (ja) |
EP (1) | EP2663186A4 (ja) |
JP (1) | JP5911514B2 (ja) |
KR (1) | KR20140092228A (ja) |
CN (1) | CN103533833B (ja) |
AU (1) | AU2012205547B2 (ja) |
BR (1) | BR112013017845A2 (ja) |
CA (1) | CA2824192A1 (ja) |
EA (1) | EA201391028A1 (ja) |
IL (1) | IL227346A0 (ja) |
MX (1) | MX2013008131A (ja) |
WO (1) | WO2012097144A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7005071B1 (ja) * | 2021-03-30 | 2022-01-21 | ▲広▼州大学 | メトホルミン塩の調製方法 |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120178813A1 (en) | 2011-01-12 | 2012-07-12 | Thetis Pharmaceuticals Llc | Lipid-lowering antidiabetic agent |
US8765811B2 (en) | 2012-07-10 | 2014-07-01 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
WO2014011814A1 (en) * | 2012-07-10 | 2014-01-16 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
US9382187B2 (en) | 2012-07-10 | 2016-07-05 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
WO2014080307A2 (en) * | 2012-11-21 | 2014-05-30 | Mahesh Kandula | Compositions and methods for the treatment of diabetes and pre-diabetes |
WO2014195810A2 (en) * | 2013-06-04 | 2014-12-11 | Mahesh Kandula | Compositions and methods for the treatment of diabetes and pre-diabetes |
EP3004049B1 (en) * | 2013-06-04 | 2018-09-05 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes and pre-diabetes |
WO2015022613A1 (en) * | 2013-08-11 | 2015-02-19 | Mahesh Kandula | Compositions and methods for the treatment of diabetes and pre-diabetes |
EP3140316A1 (en) * | 2014-05-05 | 2017-03-15 | Thetis Pharmaceuticals LLC | Compositions and methods relating to ionic salts of peptides |
DK3157936T3 (en) | 2014-06-18 | 2019-02-04 | Thetis Pharmaceuticals Llc | MINERAL AMINO ACID ACID COMPLEXES OF ACTIVE SUBSTANCES |
US9242008B2 (en) | 2014-06-18 | 2016-01-26 | Thetis Pharmaceuticals Llc | Mineral amino-acid complexes of fatty acids |
WO2016132186A1 (en) * | 2015-02-20 | 2016-08-25 | Mohan M Alapati | Compositions and methods for the treatment of hyperglycemia and metabolic syndrome |
US9371276B1 (en) * | 2015-03-21 | 2016-06-21 | Mohan Murali Alapati | Compositions and methods for the treatment of hyperglycemia and metabolic syndrome |
EP3454907B1 (en) | 2016-06-03 | 2020-07-22 | Thetis Pharmaceuticals LLC | Compositions and methods relating to salts of specialized pro-resolving mediators of inflammation |
EP3648748A1 (en) | 2017-07-06 | 2020-05-13 | Evonik Operations GmbH | Enteric coated solid dosage form comprising omega-3 fatty acid amino acid salts |
JP7050148B2 (ja) | 2017-08-15 | 2022-04-07 | エボニック オペレーションズ ゲーエムベーハー | オメガ-3脂肪酸アミノ酸塩の有効成分含有量が高い錠剤 |
WO2019120111A1 (zh) * | 2017-12-18 | 2019-06-27 | 镇学初 | 二甲双胍盐在治疗脑梗死中的用途 |
CN114206135A (zh) | 2019-08-08 | 2022-03-18 | 赢创运营有限公司 | 用于生产多不饱和脂肪酸盐的下游工艺 |
US20220287345A1 (en) | 2019-08-08 | 2022-09-15 | Evonik Operations Gmbh | Solubility enhancement of poorly soluble actives |
CN116999398A (zh) * | 2022-06-30 | 2023-11-07 | 山东海赜生物科技有限公司 | 一种口服组合物 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030220301A1 (en) * | 2002-02-14 | 2003-11-27 | Sonus Pharmaceuticals, Inc. | Metformin salts of lipophilic acids |
JP2004517105A (ja) * | 2000-12-29 | 2004-06-10 | ドファルマ | ビグアニンとキャリア、例えばメトホルミンとアルギニンの薬効的関連 |
JP2006520335A (ja) * | 2003-03-18 | 2006-09-07 | ノバルティス アクチエンゲゼルシャフト | 脂肪酸とアミノ酸を含有する組成物 |
JP2007509971A (ja) * | 2003-10-31 | 2007-04-19 | アルザ・コーポレーシヨン | メトホルミンの増加された吸収のための組成物及び投与形態物 |
US20080260819A1 (en) * | 2002-07-05 | 2008-10-23 | Collegium Pharmaceuticals Inc. | Sustained release compositions of drugs |
US20090054513A1 (en) * | 2007-08-22 | 2009-02-26 | Response Scientific, Inc. | Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease |
JP2009526033A (ja) * | 2006-02-07 | 2009-07-16 | オメガトリ エーエス | オメガ3 |
US20100021555A1 (en) * | 2004-10-15 | 2010-01-28 | Karl Geiringer | Compositions containing high omega-3 and low saturated fatty acid levels |
US20100105773A1 (en) * | 2006-11-09 | 2010-04-29 | The Children's Medical Center Corporation | Use of resolvins and docosatrienes and analogues thereof for the treatment of angiogenesis and ocular neovascularization |
JP2010516759A (ja) * | 2007-01-29 | 2010-05-20 | ハナル ファーマシューティカル カンパニー リミテッド | N,n−ジメチルイミドジカルボンイミド酸ジアミドの酢酸塩、その製造方法、及びそれを含む薬剤学的組成物 |
WO2010127099A2 (en) * | 2009-04-29 | 2010-11-04 | Amarin Corporation Plc | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
JP2010539229A (ja) * | 2007-09-21 | 2010-12-16 | ハンオル バイオファーマ カンパニー,リミテッド | N,n−ジメチルイミドジカルボンイミド酸ジアミドのジカルボン酸塩、その製造方法、及びその薬剤学的組成物 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
ATE345122T1 (de) | 2000-02-04 | 2006-12-15 | Takeda Pharmaceutical | Stabile emulsionszubereitungen |
US6491950B1 (en) | 2000-08-07 | 2002-12-10 | Kos Pharmaceuticals, Inc. | Controlled release pharmaceutical composition |
US6667064B2 (en) | 2000-08-30 | 2003-12-23 | Pilot Therapeutics, Inc. | Composition and method for treatment of hypertriglyceridemia |
US6689385B2 (en) * | 2000-11-03 | 2004-02-10 | Chronorx Llc | Formulations for the treatment of insulin resistance and type 2 diabetes mellitus |
DE10102050A1 (de) | 2001-01-17 | 2002-07-18 | Basf Ag | Zubereitung zur Verbesserung der Nahrungsverwertung |
US6881854B2 (en) | 2001-03-29 | 2005-04-19 | Basf Aktiengesellschaft | Conjugated unsaturated glyceride mixtures and a method for producing the same |
EP1429602B1 (en) | 2001-08-31 | 2009-12-16 | Rutgers, The State University Of New Jersey | Methods for treating disorders using plant extracts |
ITMI20012384A1 (it) | 2001-11-12 | 2003-05-12 | Quatex Nv | Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori |
US7670612B2 (en) | 2002-04-10 | 2010-03-02 | Innercap Technologies, Inc. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
EP2384750A1 (en) * | 2002-09-27 | 2011-11-09 | Martek Biosciences Corporation | Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid |
ITMI20022394A1 (it) | 2002-11-13 | 2004-05-14 | Bracco Spa | Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche. |
EP1510208A1 (en) | 2003-08-22 | 2005-03-02 | Fournier Laboratories Ireland Limited | Pharmaceutical composition comprising a combination of metformin and statin |
US20080045559A1 (en) | 2003-10-29 | 2008-02-21 | Sonus Pharmaceuticals, Inc. | Tocopherol-modified therapeutic drug compounds |
DE602004027936D1 (de) | 2003-10-29 | 2010-08-12 | Sonus Pharmaceutical Inc | Tocopherolmodifizierte therapeutische arzneimittelverbindung |
EP1708707A1 (en) | 2004-01-22 | 2006-10-11 | Neurosearch A/S | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist |
WO2005118612A1 (en) | 2004-06-04 | 2005-12-15 | Sonus Pharmaceuticals, Inc. | Cholesterol/bile acid/bile acid derivative-modified therapeutic anti-cancer drugs |
WO2006046156A2 (en) | 2004-10-29 | 2006-05-04 | Joan Campbell-Tofte | Anti-diabetic extract isolated from rauvolfia vomitoria and citrus aurantium, and methods of using same |
US20080200533A1 (en) | 2005-07-04 | 2008-08-21 | Ramu Krishnan | Drug or Pharmaceutical Compounds and a Preparation Thereof |
US7666898B2 (en) | 2005-11-03 | 2010-02-23 | Ilypsa, Inc. | Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors |
JP2009526747A (ja) | 2006-02-16 | 2009-07-23 | 武田薬品工業株式会社 | 環状アミン化合物および高血圧の予防・治療のための用途 |
US20090047340A1 (en) | 2006-03-29 | 2009-02-19 | Guilford F Timothy | Liposomal reduced glutathione and 1-arginine, including with other ingredient(s), capable of multipath administration for reversal and prevention of obesity and for mitochondrial biogenesis |
CN101522658A (zh) | 2006-06-16 | 2009-09-02 | 因迪基恩药物公司 | 作为抗糖尿病药用于控制糖尿病高血糖症和糖尿病并发症的二甲双胍r-(+)硫辛酸盐 |
CN101535238A (zh) | 2006-11-01 | 2009-09-16 | 普罗诺瓦生物医药挪威公司 | 作为过氧化物酶体增生物激活受体(PPAR)的活化剂或调节剂的α-取代的ω-3脂质 |
WO2008053340A1 (en) * | 2006-11-03 | 2008-05-08 | Pronova Biopharma Norge As | A combination product comprising at least one lipid substituted in the alpha position and at least one hypoglycemic agent |
US20090227560A1 (en) | 2007-04-27 | 2009-09-10 | Takanobu Kuroita | Substituted imidazole compound and use thereof |
CL2008001163A1 (es) | 2007-04-27 | 2008-12-19 | Takeda Pharmaceutical | Compuestos derivados de 1h-imidazo-4-il(piperazibn) metanona, inhibidores de renina superior, composicion farmaceutica que comprende a dichos compuestos; y uso de los compuestos para el tratamiento o prevencion de la hipertension. |
WO2009051112A1 (ja) | 2007-10-15 | 2009-04-23 | Takeda Pharmaceutical Company Limited | アミド化合物およびその用途 |
ES2645588T3 (es) | 2008-05-05 | 2017-12-05 | Oramed Ltd. | Métodos y composiciones para la administración oral de exenatida |
EA201301040A1 (ru) | 2008-06-19 | 2014-01-30 | Такеда Фармасьютикал Компани Лимитед | Гетероциклическое соединение и его применение |
US20110052678A1 (en) | 2010-11-05 | 2011-03-03 | Shantha Totada R | Method for treating age related macular degeneration |
US20120178813A1 (en) | 2011-01-12 | 2012-07-12 | Thetis Pharmaceuticals Llc | Lipid-lowering antidiabetic agent |
CA2916208A1 (en) | 2012-06-17 | 2013-12-27 | Matinas Biopharma, Inc. | Omega-3 pentaenoic acid compositions and methods of use |
-
2012
- 2012-01-11 US US13/348,265 patent/US20120178813A1/en not_active Abandoned
- 2012-01-12 EP EP12734013.1A patent/EP2663186A4/en not_active Withdrawn
- 2012-01-12 JP JP2013549539A patent/JP5911514B2/ja not_active Expired - Fee Related
- 2012-01-12 AU AU2012205547A patent/AU2012205547B2/en not_active Ceased
- 2012-01-12 CA CA2824192A patent/CA2824192A1/en not_active Abandoned
- 2012-01-12 BR BR112013017845A patent/BR112013017845A2/pt not_active IP Right Cessation
- 2012-01-12 WO PCT/US2012/021070 patent/WO2012097144A1/en active Application Filing
- 2012-01-12 EA EA201391028A patent/EA201391028A1/ru unknown
- 2012-01-12 KR KR20137018679A patent/KR20140092228A/ko not_active Application Discontinuation
- 2012-01-12 CN CN201280005222.1A patent/CN103533833B/zh not_active Expired - Fee Related
- 2012-01-12 MX MX2013008131A patent/MX2013008131A/es not_active Application Discontinuation
-
2013
- 2013-06-21 US US13/923,829 patent/US8901107B2/en not_active Expired - Fee Related
- 2013-07-04 IL IL227346A patent/IL227346A0/en unknown
- 2013-12-20 US US14/136,843 patent/US9012507B2/en not_active Expired - Fee Related
-
2014
- 2014-10-27 US US14/524,721 patent/US9216951B2/en not_active Expired - Fee Related
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004517105A (ja) * | 2000-12-29 | 2004-06-10 | ドファルマ | ビグアニンとキャリア、例えばメトホルミンとアルギニンの薬効的関連 |
US20030220301A1 (en) * | 2002-02-14 | 2003-11-27 | Sonus Pharmaceuticals, Inc. | Metformin salts of lipophilic acids |
US20080260819A1 (en) * | 2002-07-05 | 2008-10-23 | Collegium Pharmaceuticals Inc. | Sustained release compositions of drugs |
JP2006520335A (ja) * | 2003-03-18 | 2006-09-07 | ノバルティス アクチエンゲゼルシャフト | 脂肪酸とアミノ酸を含有する組成物 |
JP2007509971A (ja) * | 2003-10-31 | 2007-04-19 | アルザ・コーポレーシヨン | メトホルミンの増加された吸収のための組成物及び投与形態物 |
US20100021555A1 (en) * | 2004-10-15 | 2010-01-28 | Karl Geiringer | Compositions containing high omega-3 and low saturated fatty acid levels |
JP2009526033A (ja) * | 2006-02-07 | 2009-07-16 | オメガトリ エーエス | オメガ3 |
US20100105773A1 (en) * | 2006-11-09 | 2010-04-29 | The Children's Medical Center Corporation | Use of resolvins and docosatrienes and analogues thereof for the treatment of angiogenesis and ocular neovascularization |
JP2010516759A (ja) * | 2007-01-29 | 2010-05-20 | ハナル ファーマシューティカル カンパニー リミテッド | N,n−ジメチルイミドジカルボンイミド酸ジアミドの酢酸塩、その製造方法、及びそれを含む薬剤学的組成物 |
US20090054513A1 (en) * | 2007-08-22 | 2009-02-26 | Response Scientific, Inc. | Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease |
JP2010539229A (ja) * | 2007-09-21 | 2010-12-16 | ハンオル バイオファーマ カンパニー,リミテッド | N,n−ジメチルイミドジカルボンイミド酸ジアミドのジカルボン酸塩、その製造方法、及びその薬剤学的組成物 |
WO2010127099A2 (en) * | 2009-04-29 | 2010-11-04 | Amarin Corporation Plc | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7005071B1 (ja) * | 2021-03-30 | 2022-01-21 | ▲広▼州大学 | メトホルミン塩の調製方法 |
Also Published As
Publication number | Publication date |
---|---|
US20140107360A1 (en) | 2014-04-17 |
US20130281535A1 (en) | 2013-10-24 |
JP5911514B2 (ja) | 2016-04-27 |
US9012507B2 (en) | 2015-04-21 |
WO2012097144A1 (en) | 2012-07-19 |
US20150051284A1 (en) | 2015-02-19 |
US20120178813A1 (en) | 2012-07-12 |
CN103533833A (zh) | 2014-01-22 |
CN103533833B (zh) | 2016-08-31 |
AU2012205547B2 (en) | 2015-08-27 |
EA201391028A1 (ru) | 2013-12-30 |
MX2013008131A (es) | 2014-01-08 |
BR112013017845A2 (pt) | 2019-09-24 |
CA2824192A1 (en) | 2012-07-19 |
IL227346A0 (en) | 2013-09-30 |
EP2663186A1 (en) | 2013-11-20 |
EP2663186A4 (en) | 2014-09-24 |
US9216951B2 (en) | 2015-12-22 |
AU2012205547A1 (en) | 2013-08-01 |
KR20140092228A (ko) | 2014-07-23 |
US8901107B2 (en) | 2014-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5911514B2 (ja) | 脂質低下抗糖尿病薬 | |
US7973073B2 (en) | Antidiabetic agent for control of diabetic hyperglycemia and diabetic complications | |
US20220249463A1 (en) | Methods of altering cardiac remodeling using compounds that promote glucose oxidation | |
US8933124B2 (en) | Tri-salt form of metformin | |
US8853259B2 (en) | Metformin derivatives for treating diabetes and diabetes complications | |
WO2014011814A1 (en) | Tri-salt form of metformin | |
US20140024708A1 (en) | Ursolic acid salts for treating diabetes and obesity | |
TW516959B (en) | Composition containing ascorbic acid | |
US20090318454A1 (en) | Novel antioxidants and methods of treatment | |
WO2014008374A2 (en) | Combination therapies comprising metformin salts and antihyperglycemia agents or antihyperlipidemia agents | |
US8440723B2 (en) | Metformin salts of salicylic acid and its congeners | |
US9382187B2 (en) | Tri-salt form of metformin | |
US20170362237A1 (en) | Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications | |
JP2008524129A (ja) | うっ血性心不全の治療のためのppar作動薬の使用 | |
US20140228319A1 (en) | Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications | |
US20190263825A1 (en) | Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150113 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150113 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150729 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150817 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151116 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160229 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160329 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5911514 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |